MENU
AEON
Stock ticker: ASE
PRICE
CHANGE
CAPITALIZATION

AEON stock forecast, quote, news & analysis

AEON Biopharma Inc is a biopharmaceutical company focused on the development of ABP-450 (prabotulinumtoxinA), a biosimilar to Botox (onabotulinumtoxinA), for therapeutic indications... Show more

AEON
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for AEON with price predictions
Sep 11, 2026

AEON in +41.52% Uptrend, rising for three consecutive days on September 11, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where AEON advanced for three days, in 153 of 195 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where AEON's RSI Indicator exited the oversold zone, 25 of 34 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 74%.

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 30 of 54 cases where AEON's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 56%.

The Momentum Indicator moved above the 0 level on August 27, 2026. You may want to consider a long position or call options on AEON as a result. In 50 of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 56%.

AEON moved above its 50-day moving average on September 11, 2026 date and that indicates a change from a downward trend to an upward trend.

AEON may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where AEON declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.

The Aroon Indicator for AEON entered a downward trend on August 31, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 1 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 35 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (19.994). P/E Ratio (0.332) is within average values for comparable stocks, (27.689). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.527). Dividend Yield (0.000) settles around the average of (0.019) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (427.627).

The Tickeron Price Growth Rating for this company is 66 (best 1 - 100 worst), indicating fairly steady price growth. AEON’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AEON’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Nektar Therapeutics (NASDAQ:NKTR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 130.64B. VRTX holds the highest valuation in this group at 130.64B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -6%. For the same Industry, the average monthly price growth was -3%, and the average quarterly price growth was 2,532%. INDP experienced the highest price growth at 127%, while GOSS experienced the biggest fall at -99%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 29%. For the same stocks of the Industry, the average monthly volume growth was -8% and the average quarterly volume growth was -26%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 78
Price Growth Rating: 56
SMR Rating: 93
Profit Risk Rating: 92
Seasonality Score: -12 (-100 ... +100)
View a ticker or compare two or three
AEON
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Details
Industry
N/A
Address
5 Park Plaza
Phone
+1 949 354-6499
Employees
8
Web
https://www.aeonbiopharma.com
AEON in +41.52% Uptrend, rising for three consecutive days on September 11, 2026